It’s nice to have more tools in the toolbox so that we’re not trying to fit a square peg in a round hole,” one expert says.

SIRONA tested the sirolimus DCB against seven commercially available paclitaxel DCBs. The study randomized 482 patients (mean ...

Underdiagnosis and undertreatment likely drive the profound effects observed in certain populations, says Juan Granada.

At 6 months, the win ratio favored the device over optimal medical therapy, in large part driven by improved quality of life.

The IRIS-MAIN registry results did show some differences in nonfatal outcomes like stroke, MI, and revascularization.

The postapproval study makes the case that Symplicity Spyral reduces BP across a wide swath of real-world populations.

SIMPLAAFY was a multicenter, open-label trial that included 1,857 patients (mean age 76 years; 43% women) with AF who underwent LAAO with the Watchman FLX Pro device (Boston Scientific) without ...

The population was enriched with a sicker phenotype than prior trials, which may have enhanced the impact on hard outcomes.

The study showed notable sex-based differences, as well as a trend toward better survival in those who got an intervention.

The trial is “a turning point” in the management of moderate AS, says Philippe Généreux, adding that the disease is not benign.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...